Managing Adverse Events With Selinexor in R/R Multiple Myeloma
June 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status
May 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLC
May 25th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung cancer.
Physicians Discuss When to Use a PARP Inhibitor in mCRPC
May 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.
Physicians Discuss Recommended Therapies for R/R Multiple Myeloma
May 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.
Long-Term Combination Data Show Most Benefit in Second-Line DLBCL
May 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Areas of Concern in Using Amivantamab and Mobocertinib in EGFR Exon 20+ NSCLC
May 11th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed with participants how they would use the FDA-approved therapies amivantamab and mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion alteration. This is the second of 2 articles based on this event.
Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer
May 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.
Dosing and Toxicity: Considerations for Administering Teclistamab in R/R Multiple Myeloma
May 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Shaji Kumar, MD, discussed with participants the key considerations of administering the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
MajesTEC-1 Results Show Efficacy for Teclistamab in Multiple Myeloma
May 9th 2023In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.
Nivolumab/Relatlimab Shows PFS/OS Benefit Over Nivolumab in Melanoma
May 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed data from the RELATIVITY-047 trial of nivolumab plus relatlimab for patients with metastatic melanoma. This is the second of 2 articles based on this event.
Choosing Between Tivozanib and Lenvatinib/Everolimus in Third-Line RCC
May 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Real-World Factors Influence Choice of IO/TKI Regimen for mRCC
May 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Amivantamab Compared With Real-World EGFR Exon 20 NSCLC Population
April 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.
Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer
April 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.
Roundtable Discussion: Khan Reviews Systemic Therapy for Relapsed/Refractory DLBCL
April 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus Khan, MD, discussed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was referred for chimeric antigen receptor T-cell therapy and was place on a waiting list for treatment.